Niagen Bioscience, Inc. (NAGE)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 29/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.71% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Niagen Bioscience to Present at LD Micro 20th Annual Main Event
- Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®" a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
- Niagen Bioscience (NAGE): Can Its NAD+ Business Drive the Next Leg of Growth?
- Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
- Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
- Niagen Bioscience to Present at Longevity Investors Conference
- Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
- Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Niagen Bioscience, Inc..
Full NAGE Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.